Related Experiment Video
Updated: Jul 16, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Perioperative Systemic Therapies in Resectable Non-Small Cell Lung Cancer: Opportunities and Challenges.
Natalia Kwiatkowska1,2, Alain Gelibter3, Piotr Gabryel1
1Department of Thoracic Surgery, Poznan University of Medical Sciences, 60-569 Poznan, Poland.
Journal of Clinical Medicine
|July 15, 2026
Summary
Preoperative immunotherapy improves outcomes for non-small cell lung cancer (NSCLC) patients. Optimizing patient selection and surgical approaches enhances treatment efficacy and patient results.
Area of Science:
- Oncology
- Immunotherapy
- Thoracic Surgery
Background:
- Recent immunotherapy advancements have significantly improved outcomes for non-small cell lung cancer (NSCLC) patients.
- This review focuses on the outcomes of preoperative immunotherapy in NSCLC treatment from 2020 to 2025.
Purpose of the Study:
- To synthesize current literature on preoperative immunotherapy for NSCLC.
- To analyze treatment regimens, surgical outcomes, and adverse events associated with this approach.
Main Methods:
- Literature review of studies published between 2020 and 2025.
- Analysis of primary endpoints, surgical rates, R0 resection rates, and adverse events.
- Evaluation of surgery delays and cancellations in the context of preoperative immunotherapy.
Main Results:
- Key findings highlight the need for optimized patient selection and effective management of immune-related adverse events.
- Strategies to minimize surgical delays and cancellations are crucial for successful preoperative immunotherapy implementation.
- Minimally invasive surgeries and avoidance of pneumonectomies are identified as areas for improvement.
Conclusions:
- Optimizing patient selection and managing adverse events are critical for enhancing preoperative immunotherapy efficacy in NSCLC.
- Increasing the adoption of minimally invasive surgical techniques and reducing pneumonectomies are priorities for improving patient outcomes.
- These strategies are essential for maximizing the benefits of immunotherapy in the surgical management of NSCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...